Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
461.57
USD
+12.19 (+2.71%)
Official Closing Price
Updated: 7:58 PM EST, Mar 5, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All news about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
4 SPACs for the Future
March 06, 2021
A rocket company, a 3-D capture software company, and two biotechs are about to hit the public markets. Smart investors can get in now via special purpose acquisition companies.
Tags
GOOGL
RDFN
GOOG
From
Motley Fool
Is BioNTech Stock a Buy?
March 05, 2021
The key ingredients are here for a multi-bagger over the next decade and beyond.
Tags
REGN
NVAX
JNJ
From
Motley Fool
The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company
March 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
Tags
GLTO
KPTI
EYPT
From
Benzinga
Sanofi/Regneron's Dupixent Application For Asthma In Children Accepted For FDA Review
March 04, 2021
TheFDA has accepted for reviewthe supplemental marketing application seeking approval for Dupixent (dupilumab). It is an ...
Tags
Benzinga
Market News
General
From
Benzinga
FDA accepts Dupixent® (dupilumab) for review in children with moderate-to-severe asthma
March 04, 2021
From
GlobeNewswire News Releases
FDA Accepts Dupixent® (dupilumab) for Review in Children with Moderate-to-severe Asthma
March 04, 2021
From
PR Newswire
Vir Stock Craters On Weak Data For GSK-Partnered Covid Treatment
March 03, 2021
Emerging data cast doubt on the effectiveness of Vir Biotechnology and GlaxoSmithKline's coronavirus treatment, leading Vir stock to plummet on Wednesday. Shares plunged more than 30%.
From
Investor's Business Daily
ACWV, WM, REGN, GILD: Large Outflows Detected at ETF
March 03, 2021
Symbols mentioned in this story: ACWV, WM, REGN, GILD Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units''...
Tags
ETFs
From
ETF Channel
Noteworthy Monday Option Activity: RAD, REGN, HURN
March 01, 2021
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Rite Aid Corp (RAD), where a total volume of 19,413 contracts has been traded thus...
Tags
Stocks
From
Market News Video
Regeneron's Single-Dose REGN1908-1909 Shows Rapid, Durable Benefit In Cat-Allergic Asthma Patients
March 01, 2021
Regeneron Pharmaceuticals Inc(NASDAQ:REGN) hasannounced detailed resultsfrom a Phase 2 proof-of-concept trial ...
Tags
Benzinga
Market News
General
From
Benzinga
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
February 28, 2021
Most Food and Drug Administration decisions scheduled for February were positive, and more importantly five new molecular entities ...
Tags
SRPT
FDA
LLY
From
Benzinga
Retail, Tech Earnings, and Berkshire's Surprising Buys
February 27, 2021
Our Fools talk about fourth-quarter results, as well as the loss of a great CEO.
Tags
AMZN
PGRE
CVX
From
Motley Fool
Regeneron Announces Positive Phase 2 Data Evaluating Fel d 1 Antibody Cocktail in Cat-allergic Patients with Mild Asthma
February 27, 2021
From
PR Newswire
Regeneron's COVID-19 Antibody Cocktail Wins EU Positive Opinion
February 26, 2021
Regeneron Pharmaceuticals Inc(NASDAQ:REGN) hasreceived a positive opinionfrom European Medicines Agency's ...
Tags
RHHVF
CHMP
RHHBY
From
Benzinga
First Week of REGN August 20th Options Trading
February 26, 2021
Investors in Regeneron Pharmaceuticals, Inc. (REGN) saw new options become available this week, for the August 20th expiration..
Tags
Stocks
From
Market News Video
Coronavirus Mutations: Why The Battle Against Covid Is Just Beginning
February 26, 2021
The battle against Covid-19 is about to get uglier. Coronavirus mutations threaten to undercut a year's worth of work upholding Covid stocks like Pfizer, Moderna and Regeneron Pharmaceuticals.
From
Investor's Business Daily
EMA Issues Advice on Regeneron's Antibody Cocktail (casirivimab with imdevimab) for Certain COVID-19 Patients
February 26, 2021
From
PR Newswire
Akari Therapeutics' PASylated Nomacopan Shows Promising Action In Animal Studies
February 25, 2021
Akari Therapeutics Plc(NASDAQ:AKTX)announces new datafrom PASylated nomacopan published in the journal ...
Tags
Biotech
News
AKTX
From
Benzinga
Positive news on COVID vaccines weighs against concerns over new variants
February 25, 2021
The COVID-19 vaccine developed by Pfizer Inc. and German partner BioNTech SE has proved to be as effective in the real world as it was in clinical trials in the first major study of the two-dose...
Tags
GSK
SPX
REGN
From
MarketWatch
Regeneron To Stop Giving Placebo In COVID-19 Antibody Trial After 'Clear Efficacy'
February 25, 2021
Following recommendationsfrom the Independent Data Monitoring Committee (IDMC),Regeneron Pharmaceuticals ...
Tags
Benzinga
Market News
General
From
Benzinga
Independent Data Monitoring Committee Finds Clear Efficacy for REGEN-COV™ (casirivimab with imdevimab) in Phase 3 COVID-19 Outpatient Outcomes Trial
February 25, 2021
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced changes to the Phase 3 trial assessing investigational REGEN-COV™ (casirivimab with imdevimab) in non-hospitalized patients...
From
PR Newswire
Decibel Therapeutics' Hearing Loss Gene Therapy Shows Potential In Preclinical Studies
February 24, 2021
Decibel Therapeutics Inc(NASDAQ:DBTX)presented preclinical dataof its gene therapy candidate, DB-OTO, for ...
Tags
Market News
Hearing loss
Health Care
From
Benzinga
Promising Oncology Breakthroughs Sparking Wave of Next Generation of Brain Cancer Therapies
February 24, 2021
Tags
Featured News
From
FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Promising Oncology Breakthroughs Sparking Wave of Next Generation of Brain Cancer Therapies
February 24, 2021
FN Media Group Presents USA News Group News Commentary
From
PR Newswire
RLFTF: Why Little-Known Relief Therapeutics Is Climbing Today
February 24, 2021
<p><a rel="nofollow" href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice & Trading Tips</a></p> <p>Shares of little-known biopharma firm Relief Therapeutics gained on...
Tags
CDMO
LLY
RLFTF
From
InvestorPlace
Opthea Outlines OPT-302 Pivotal Study Designs In Chronic Eye Disorder
February 24, 2021
Following consultations with FDA and European Medical Agency,OptheaNASDAQ: OPT) hasfinalized trial designsfor ...
Tags
FDA
Health Care
Age/Related Macular Degeneration
From
Benzinga
Why You Should Keep Your Distance from Ocugen Stock
February 23, 2021
<p><a rel="nofollow" href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice & Trading Tips</a></p> <p>Off and on the price chart OCGN stock, today's reality is bleak for...
Tags
MRNA
NASDAQ:OCGN,NYSE:PFE,NYSE:JNJ,NASDAQ:REGN,NYSE:AZN,NASDAQ:MRNA
PFE
From
InvestorPlace
Sanofi/Regeneron's DUPIXENT Wins Canada Approval For Atopic Dermatitis In Children Aged 6-11
February 23, 2021
Health Canada has approvedSanofi’s SA(NASDAQ:SNY) andRegeneron Pharmaceuticals ...
Tags
Market News
atopic dermatitis
Health Care
From
Benzinga
2 Best Pharma Stocks to Buy Right Now
February 23, 2021
These under-appreciated pharma stocks have the potential to become long-term winners.
Tags
BIIB
REGN
Market News
From
Motley Fool
FDA Approves Regeneron/Sanofi's Libtayo For Front-Line Lung Cancer
February 23, 2021
The FDA approved expanded use ofRegeneron Pharmaceuticals Inc(NASDAQ:REGN) andSanofi’s ...
Tags
Biotech
News
A
From
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.